UK Markets open in 7 hrs 58 mins

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
292.39-2.53 (-0.86%)
At close: 4:00PM EDT
297.01 +4.62 (+1.58%)
After hours: 07:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close294.92
Bid295.50 x 1100
Ask299.14 x 1100
Day's range290.76 - 304.35
52-week range75.35 - 464.00
Avg. volume4,141,190
Market cap70.618B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings date09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est332.87
  • Business Wire

    FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years

    NEW YORK & MAINZ, Germany, October 26, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12 years of age. VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters,

  • Globe Newswire

    BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022

    BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is planned to be initiated in mid-2022First manufacturing facility will become a node in a decentralized and robust African end-to-end manufacturing network Development and implementation of a scalable regional manufacturing network to enable an annual manufacturing capacity of several hundreds of million mRNA vaccine doses MAINZ, G

  • Motley Fool

    Why Pfizer and BioNTech Will Be Bigger Winners Than Moderna With Mix-and-Match Boosters

    Last week, the U.S. Food and Drug Administration (FDA) authorized the use of "mix-and-match" COVID-19 vaccine boosters. Any person eligible to receive a booster won't have to stick with the same vaccine used in their primary vaccination. This FDA decision opens the door to even more of a contest between the three COVID-19 vaccines currently available in the U.S. That's especially the case between the two most widely adopted vaccines.